56,800 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Pennant Investors LP

Pennant Investors LP purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 56,800 shares of the company’s stock, valued at approximately $586,000. Nurix Therapeutics accounts for approximately 0.1% of Pennant Investors LP’s holdings, making the stock its 12th largest holding. Pennant Investors LP owned 0.12% of Nurix Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in NRIX. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock valued at $58,000 after purchasing an additional 4,367 shares during the period. Quest Partners LLC acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at approximately $59,000. International Assets Investment Management LLC acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at approximately $1,175,000. Jump Financial LLC acquired a new position in shares of Nurix Therapeutics in the fourth quarter valued at approximately $158,000. Finally, Principal Financial Group Inc. increased its holdings in shares of Nurix Therapeutics by 14.8% in the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock valued at $122,000 after purchasing an additional 2,002 shares during the period.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 3,499 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total value of $44,892.17. Following the sale, the chief financial officer now owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Houte Hans Van sold 3,499 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total value of $44,892.17. Following the sale, the chief financial officer now owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christine Ring sold 1,596 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $17.01, for a total value of $27,147.96. Following the completion of the sale, the insider now directly owns 19,838 shares in the company, valued at approximately $337,444.38. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,889 shares of company stock worth $119,704. 9.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on NRIX shares. Wells Fargo & Company decreased their price target on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, February 16th. Morgan Stanley boosted their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Stephens began coverage on Nurix Therapeutics in a research report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 target price on the stock. Piper Sandler restated an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, June 5th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Nurix Therapeutics Stock Up 4.0 %

Shares of NRIX traded up $0.62 during mid-day trading on Tuesday, hitting $15.94. The stock had a trading volume of 140,937 shares, compared to its average volume of 918,915. The company has a market cap of $783.45 million, a PE ratio of -5.90 and a beta of 2.17. The company’s fifty day simple moving average is $14.74 and its two-hundred day simple moving average is $11.77. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.04. The company had revenue of $16.59 million during the quarter, compared to analyst estimates of $14.58 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. Equities analysts expect that Nurix Therapeutics, Inc. will post -3 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.